3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
17
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
3
Hematologic Neoplasms
2
Teratoma
1
Stroke
1
Pulmonary Disease, Chronic Obstructive
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Kidney Failure, Chronic
1
Hepatitis B
1
Hematopoietic and Lymphatic System Neoplasm
1
Endometrial Clear Cell Adenocarcinoma
1
Endodermal Sinus Tumor
1
Diabetes Mellitus
1
Coronary Artery Disease
1
Colonic Neoplasms
1
Carcinoma, Embryonal
1
COVID-19
1
Breast Neoplasms
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Carboplatin
66
Cisplatin
57
Paclitaxel
42
Radiotherapy
35
Pemetrexed
34
Gemcitabine
31
Docetaxel
31
Etoposide
24
pembrolizumab
21
Vinorelbine
20
Erlotinib Hydrochloride
13
Magnetic Resonance Spectroscopy
12
Gefitinib
11
Specimen Handling
10
Radiosurgery
10
Drug Therapy
10
Bevacizumab
10
durvalumab
9
Nivolumab
9
Vinblastine
6
Topotecan
6
Surgical Procedures, Operative
6
Cyclophosphamide
6
Standard of Care
5
Platinum
5
Immunoglobulin G
5
Ifosfamide
5
Disulfides
5
Dexamethasone
5
paclitaxel poliglumex
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lung Neoplasms
×
Practice Guidelines as Topic
×
Clear all
NCT06563388
2026-02-04
ID-COMET
Roswell Park Cancer Institute
Phase 3
Recruiting
800 enrolled